Microvast Reports First Quarter 2025 Financial Results
Record company Q1 revenue, increased 43.2% year over year to
$116.5 million Gross margin increased from 21.2% to 36.9%, a 15.7 percentage point improvement year over year
"Building on our strong momentum from 2024,
Results for Q1 2025
Record first quarter revenue of
$116.5 million , compared to$81.4 million in Q1 2024, an increase of 43.2%
Gross margin increased to 36.9% from 21.2% in Q1 2024; Non-GAAP adjusted gross margin increased to 37.0%, up from 22.6% in Q1 2024
Operating expenses of
$25.5 million , compared to$40.9 million in Q1 2024; Non-GAAP adjusted operating expenses of$24.9 million , compared to$30.1 million in Q1 2024
Net profit of
$61.8 million , compared to net loss of$24.8 million in Q1 2024; Non-GAAP adjusted net profit of$19.3 million , compared to non-GAAP adjusted net loss of$13.0 million in Q1 2024
Net profit per share of
$0.19 compared to net loss per share of$0.08 in Q1 2024; Non-GAAP adjusted net profit per share of$0.06 , compared to non-GAAP adjusted net loss per share of$0.04 in Q1 2024
Non-GAAP adjusted EBITDA of positive
$28.5 million in Q1 2025, compared to non-GAAP adjusted EBITDA of negative$3.7 million in Q1 2024
Capital expenditures of
$6.6 million , compared to$10.2 million in Q1 2024
Cash, cash equivalents, restricted cash and short-term investments of
$123.0 million as ofMarch 31, 2025 , compared to$109.6 million as ofDecember 31, 2024 , and$86.7 million as ofMarch 31, 2024
Please refer to the tables at the end of this press release for reconciliations of gross profit to non-GAAP adjusted gross profit, operating expenses to non-GAAP adjusted operating expenses, net profit/(loss) to non-GAAP adjusted net profit/(loss), net profit/(loss) to non-GAAP adjusted EBITDA and gross margin to non-GAAP adjusted gross margin.
2025 Outlook
For the remainder of 2025, the Company maintains its target revenue growth of 18% to 25% year over year and revenue guidance of
$450 million to$475 million
Through 2025, with continued regional efficiencies and utilization increases, the Company is targeting a gross margin of 30%
Installation of production equipment for Huzhou Phase 3.2, increasing our capacity to meet strong customer demand and targeting first qualified products in Q4 2025
Sustained focus on new customer wins that will continue to expand our presence in differentiated commercial vehicle markets as OEM product lines and segments continue to electrify
Webcast Information
Company management will host a conference call and webcast on
About
For more information, please visit www.microvast.com or follow us on LinkedIn (@microvast).
Contact:
Investor Relations
ir@microvast.com
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our future results of operations and financial position, our operational performance, our anticipated growth and business strategy, our future capital expenditures and debt service obligations, the projected costs, prospects and plans and objectives of management for future operations, including regarding expected growth and demand for our batteries and energy storage solutions and introduction of new batteries and energy storage solutions, the adoption of such offerings by customers, our expectations relating to backlog, pipeline and contracted backlog, our ability to implement our remediation plan in connection with the material weakness in our internal control over financial reporting, current expectations relating to legal proceedings and anticipated impacts and benefits from the Inflation Reduction Act of 2022 as well as any other proposed or recently enacted legislation. In some cases, you may also identify forward-looking statements by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “plan,” “project,” “predict,” “outlook” “should,” “will,” “would,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Such forward-looking statements are based upon the current beliefs and expectations of management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements.
Many factors could cause actual results and the timing of events to differ materially from the anticipated results or other expectations expressed in the forward-looking statements, including, among others: (1) our ability to remain a going concern; (2) risk that we may not be able to execute our growth strategies or achieve profitability; (3) risk that we will be unable to raise additional capital to execute our business plan or pay our debts as they come due, which may not be available on acceptable terms or at all; (4) potential difficulties in maintaining manufacturing capacity and establishing expected mass manufacturing capacity in the future; (5) risks relating to delays, disruptions and quality control problems in our manufacturing operations; (6) restrictions in our existing and any future credit facilities; (7) risks of operations in
Actual results, performance or achievements may differ materially, and potentially adversely, from any forward-looking statements and the assumptions on which those forward-looking statements are based. There can be no assurance that the data contained herein is reflective of future performance to any degree. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as forward-looking statements are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control.
All information set forth herein speaks only as of the date hereof, and we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date hereof except as may be required under applicable securities laws. Forecasts and estimates regarding our industry and end markets are based on sources we believe to be reliable, however, there can be no assurance these forecasts and estimates will prove accurate in whole or in part.
All references to the “Company,” “we,” “us” or “our” refer to
Non-GAAP Financial Measures
To provide investors with additional information regarding our financial results,
Reconciliations to the most comparable GAAP measures, gross profit, gross margin, operating expenses and net profit/(loss), are contained in tabular form in the unaudited financial statements below. Non-GAAP adjusted gross profit is GAAP gross profit as adjusted for non-cash stock-based compensation expense included in cost of revenues. Non-GAAP adjusted net profit/(loss) is GAAP net profit/(loss) as adjusted for non-cash stock-based compensation expense and change in valuation of warrant and Convertible loan. Non-GAAP adjusted net profit/(loss) per common share is GAAP net profit/(loss) per common share as adjusted for non-cash stock-based compensation expense and change in valuation of warrant and Convertible loan per common share. Non-GAAP adjusted EBITDA is defined as net profit/(loss) excluding depreciation and amortization, non-cash settled share-based compensation expense, interest expense, interest income, changes in fair value of our warrant and Convertible loan and income tax expense or benefit. Non-GAAP adjusted operating expenses is defined as operating expenses excluding non-cash stock-based compensation expense. Non-GAAP adjusted gross margin is defined as GAAP gross margin as adjusted for non-cash stock-based compensation expense included in cost of revenues.
We use non-GAAP adjusted gross profit, non-GAAP adjusted EBITDA, non-GAAP adjusted operating expenses, non-GAAP adjusted net profit/(loss) and non-GAAP adjusted gross margin for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We consider them to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that these non-GAAP financial measures, when taken together with their most directly comparable GAAP measures, gross profit and net profit/(loss), provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our recurring core business operating results.
We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to our historical performance. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business. Accordingly, we believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and board of directors.
Non-GAAP financial measures have limitations as an analytical tool, and you should not consider them in isolation, or as a substitute for, financial information prepared in accordance with GAAP. For example, our calculation of non-GAAP adjusted EBITDA may differ from similarly titled non-GAAP measures, if any, reported by our peer companies, or our peer companies may use other measures to calculate their financial performance, and therefore our use of non-GAAP adjusted EBITDA may not be directly comparable to similarly titled measures of other companies. The principal limitation of non-GAAP adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recorded in our financial statements. In addition, it is subject to inherent limitations as it reflects the exercise of judgments by management about which expense and income are excluded or included in determining this non-GAAP financial measure. In order to compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. In addition, such financial information is unaudited and does not conform to SEC Regulation S-X and as a result, such information may be presented differently in our future filings with the
| |||||||
, | , | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 90,898 | $ | 73,007 | |||
| Restricted cash, current | 32,096 | 36,572 | |||||
| Accounts receivable (net of allowance for credit losses of | 135,654 | 120,626 | |||||
| Notes receivable | 10,362 | 7,579 | |||||
| Inventories, net | 129,059 | 143,327 | |||||
| Prepaid expenses and other current assets | 30,027 | 27,019 | |||||
| Assets held for sale | 19,896 | 19,896 | |||||
| Total Current Assets | 447,992 | 428,026 | |||||
| Restricted cash, non-current | — | 22 | |||||
| Property, plant and equipment, net | 485,157 | 478,189 | |||||
| Land use rights, net | 11,366 | 11,371 | |||||
| Acquired intangible assets, net | 2,496 | 2,607 | |||||
| Operating lease right-of-use assets | 18,205 | 17,628 | |||||
| Other non-current assets | 17,716 | 14,024 | |||||
| Total Assets | $ | 982,932 | $ | 951,867 | |||
| Liabilities | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 56,771 | $ | 64,940 | |||
| Advance from customers | 44,204 | 43,678 | |||||
| Accrued expenses and other current liabilities | 104,136 | 98,456 | |||||
| Amounts due to related parties | — | 5 | |||||
| Income tax payables | 653 | 652 | |||||
| Short-term bank borrowings | 86,241 | 70,666 | |||||
| Notes payable | 47,901 | 51,756 | |||||
| Total Current Liabilities | 339,906 | 330,153 | |||||
| Long-term bonds payable | 41,693 | 43,157 | |||||
| Long-term bank borrowings | 41,302 | 41,062 | |||||
| Warrant liability | 64 | 290 | |||||
| Share-based compensation liability | 98 | 98 | |||||
| Operating lease liabilities | 14,793 | 14,596 | |||||
| Convertible loan measured at fair value | 60,996 | 104,613 | |||||
| Other non-current liabilities | 29,845 | 30,003 | |||||
| Total Liabilities | $ | 528,697 | $ | 563,972 | |||
| Stockholders’ Equity | |||||||
| Common Stock (par value of | $ | 33 | $ | 33 | |||
| Additional paid-in capital | 1,513,685 | 1,512,982 | |||||
| Statutory reserves | 6,032 | 6,032 | |||||
| Accumulated deficit | (1,031,168 | ) | (1,092,958 | ) | |||
| Accumulated other comprehensive loss | (34,347 | ) | (38,194 | ) | |||
| Total Equity | $ | 454,235 | $ | 387,895 | |||
| Total Liabilities and Equity | $ | 982,932 | $ | 951,867 | |||
| |||||||
| Three Months Ended | |||||||
| 2025 | 2024 | ||||||
| Revenues | $ | 116,491 | $ | 81,351 | |||
| Cost of revenues | (73,475 | ) | (64,126 | ) | |||
| Gross profit | 43,016 | 17,225 | |||||
| Operating expenses: | |||||||
| General and administrative expenses | (10,453 | ) | (23,794 | ) | |||
| Research and development expenses | (8,248 | ) | (11,492 | ) | |||
| Selling and marketing expenses | (6,799 | ) | (5,591 | ) | |||
| Total operating expenses | (25,500 | ) | (40,877 | ) | |||
| Subsidy income | 1,416 | 534 | |||||
| Profit/(loss) from operations | 18,932 | (23,118 | ) | ||||
| Other income and expenses: | |||||||
| Interest income | 177 | 119 | |||||
| Interest expense | (1,188 | ) | (1,732 | ) | |||
| Changes in fair value of warrant liability and convertible loan | 43,160 | 42 | |||||
| Gain on debt restructuring | 389 | — | |||||
| Other income/(expense), net | 320 | (136 | ) | ||||
| Profit/(loss) before provision for income taxes | 61,790 | (24,825 | ) | ||||
| Income tax expense | — | — | |||||
| Net profit/(loss) | $ | 61,790 | $ | (24,825 | ) | ||
| Less: net profit/(loss) attributable to noncontrolling interests | — | — | |||||
| Net profit/(loss) attributable to | $ | 61,790 | $ | (24,825 | ) | ||
| Net profit/(loss) per common share | |||||||
| Basic | $ | 0.19 | $ | (0.08 | ) | ||
| Diluted | $ | 0.05 | $ | (0.08 | ) | ||
| Weighted average shares used in calculating net profit/(loss) per share of common stock | |||||||
| Basic | 323,430,721 | 315,367,121 | |||||
| Diluted | 374,425,026 | 315,367,121 | |||||
| |||||||
| Three Months Ended | |||||||
| 2025 | 2024 | ||||||
| Cash flows from operating activities | |||||||
| Net profit/(loss) | $ | 61,790 | $ | (24,825 | ) | ||
| Adjustments to reconcile net profit/(loss) to net cash used in operating activities: | |||||||
| Loss/(gain) on disposal of property, plant and equipment | 95 | (34 | ) | ||||
| Gain on debt restructuring | (389 | ) | — | ||||
| Depreciation of property, plant and equipment | 7,985 | 7,470 | |||||
| Amortization of land use right and intangible assets | 192 | 194 | |||||
| Noncash lease expenses | 666 | 664 | |||||
| Share-based compensation | 703 | 11,865 | |||||
| Changes in fair value of warrant and convertible loan | (43,160 | ) | (42 | ) | |||
| Allowance of credit losses | 1,358 | 578 | |||||
| Product warranty | 4,825 | 3,269 | |||||
| Changes in operating assets and liabilities: | |||||||
| Notes receivable | (5,263 | ) | 10,577 | ||||
| Accounts receivable | (14,108 | ) | 12,011 | ||||
| Inventories | 15,783 | 16,341 | |||||
| Prepaid expenses and other current assets | (2,402 | ) | 4,305 | ||||
| Amounts due to related parties | (5 | ) | — | ||||
| Operating lease right-of-use assets | (654 | ) | (323 | ) | |||
| Other non-current assets | (1,388 | ) | (275 | ) | |||
| Notes payable | (4,150 | ) | 1,042 | ||||
| Accounts payable | (8,547 | ) | (27,843 | ) | |||
| Advance from customers | 462 | (1,694 | ) | ||||
| Accrued expenses and other liabilities | (6,812 | ) | (10,623 | ) | |||
| Operating lease liabilities | (340 | ) | (500 | ) | |||
| Other non-current liabilities | 528 | (126 | ) | ||||
| Net cash generated from operating activities | 7,169 | 2,031 | |||||
| Cash flows from investing activities | |||||||
| Purchases of property, plant and equipment | (2,346 | ) | (10,241 | ) | |||
| Proceeds on disposal of property, plant and equipment | 14 | 152 | |||||
| Proceeds from maturity of short-term investments | — | 5,564 | |||||
| Net cash used in investing activities | (2,332 | ) | (4,525 | ) | |||
| |||||||
| Three Months Ended | |||||||
| 2025 | 2024 | ||||||
| Cash flows from financing activities | |||||||
| Proceeds from borrowings | 28,187 | 18,780 | |||||
| Repayment of bank borrowings | (13,062 | ) | (12,520 | ) | |||
| Repayment of bonds payable | (1,375 | ) | — | ||||
| Deferred payment related to purchases of property, plant and equipment | (4,287 | ) | — | ||||
| Net cash generated from financing activities | 9,463 | 6,260 | |||||
| Effect of exchange rate changes | (907 | ) | (5,251 | ) | |||
| Increase/ (decrease) in cash, cash equivalents and restricted cash | 13,393 | (1,485 | ) | ||||
| Cash, cash equivalents and restricted cash at beginning of the period | 109,601 | 88,189 | |||||
| Cash, cash equivalents and restricted cash at end of the period | $ | 122,994 | $ | 86,704 | |||
| Three Months Ended | |||||||
| 2025 | 2024 | ||||||
| Reconciliation to amounts on consolidated balance sheets | |||||||
| Cash and cash equivalents | $ | 90,898 | $ | 39,451 | |||
| Restricted cash | 32,096 | 47,253 | |||||
| Total cash, cash equivalents and restricted cash | $ | 122,994 | $ | 86,704 | |||
| |||||||
| Three Months Ended | |||||||
| 2025 | 2024 | ||||||
| Revenues | $ | 116,491 | $ | 81,351 | |||
| Cost of revenues | (73,475 | ) | (64,126 | ) | |||
| Gross profit (GAAP) | $ | 43,016 | $ | 17,225 | |||
| Gross margin | 36.9 | % | 21.2 | % | |||
| Non-cash settled share-based compensation (included in cost of revenues) | 62 | 1,138 | |||||
| Adjusted gross profit (non-GAAP) | $ | 43,078 | $ | 18,363 | |||
| Adjusted gross margin (non-GAAP) | 37.0 | % | 22.6 | % | |||
| |||||||
| Three Months Ended | |||||||
| 2025 | 2024 | ||||||
| General and administrative expenses | (10,453 | ) | (23,794 | ) | |||
| Research and development expenses | (8,248 | ) | (11,492 | ) | |||
| Selling and marketing expenses | (6,799 | ) | (5,591 | ) | |||
| Operating expenses (GAAP) | $ | (25,500 | ) | $ | (40,877 | ) | |
| Non-cash settled share-based compensation (included in Operating expenses) | 641 | 10,729 | |||||
| Adjusted operating expenses (non-GAAP) | $ | (24,859 | ) | $ | (30,148 | ) | |
| |||||||
| Three Months Ended | |||||||
| 2025 | 2024 | ||||||
| Net profit/(loss) (GAAP) | $ | 61,790 | $ | (24,825 | ) | ||
| Changes in fair value of warrant and Convertible loan* | (43,160 | ) | (42 | ) | |||
| Non-cash settled share-based compensation* | 703 | 11,867 | |||||
| Adjusted net profit/(loss) (non-GAAP) | $ | 19,333 | $ | (13,000 | ) | ||
*The tax effect of the adjustments was nil.
| Three Months Ended | |||||||
| 2025 | 2024 | ||||||
| Net profit/(loss) per common share-Basic (GAAP) | $ | 0.19 | $ | (0.08 | ) | ||
| Changes in fair value of warrant and Convertible loan per common share | (0.13 | ) | — | ||||
| Non-cash settled share-based compensation per common share | — | 0.04 | |||||
| Adjusted net profit/(loss) per common share-Basic (non-GAAP) | $ | 0.06 | $ | (0.04 | ) | ||
| |||||||
| Three Months Ended | |||||||
| 2025 | 2024 | ||||||
| Net profit/(loss) (GAAP) | $ | 61,790 | $ | (24,825 | ) | ||
| Interest expense (income), net | 1,011 | 1,613 | |||||
| Income tax expense | — | — | |||||
| Depreciation and amortization | 8,177 | 7,664 | |||||
| EBITDA (non-GAAP) | $ | 70,978 | $ | (15,548 | ) | ||
| Changes in fair value of warrant liability and convertible loan | (43,160 | ) | (42 | ) | |||
| Non-cash settled share-based compensation | 703 | 11,867 | |||||
| Adjusted EBITDA (non-GAAP) | $ | 28,521 | $ | (3,723 | ) | ||
